Extended-release ketamine tablets offer new hope for treatment-resistant depression

FHS
June 26, 2024
4:17 am

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects.

Senate Republicans Again Block Legislation to Guarantee Women’s Rights to IVF

Republicans have blocked for a second time this year legislation to establish a nationwide right to in vitro fertilization (IVF), arguing that the vote is

September 19, 2024

For pharma companies, green chemistry possibilities are huge

“Green” or “sustainable” chemistry has been gaining momentum since the 1990s. It is based on 12 principles, which include decreasing waste at a molecular level,

October 30, 2024

MindMed Reports Second Quarter 2024 Financial Results and Business Updates | Psychedelic Invest

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced

August 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.